The CHAMPION-NMOSD trial (NCT04201262) is a global, open-label, multicentre, phase 3, externally controlled study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In this touchNEUROLOGY interview, we caught up with Prof. Sean Pittock (Mayo Clinic, Rochester, MN, USA) to discuss the pre-specified efficacy analyses in clinically relevant patient subgroups, and the effect ravulizumab may have on clinical practice if approved. Prof. Pittock also discusses the current treatment options available, and the challenges that arise in cost, access and diagnosis, such as the role that biomarkers play in diagnosing NMOSD globally.
The abstract entitled ‘Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder’ (Abstract #P010) was presented at ECTRIMS, 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 26 – 28 October 2022, Amsterdam, the Netherlands.
- What subgroup analyses were prespecified in the CHAMPION-NMOSD study? (0:30)
- What unanswered questions remain and what future studies are planned? (2:03)
- If approved, what will be the impact of ravulizumab on clinical practice? (4:47)
Disclosures: Prof. Sean Pittcock is a consultant for, and receives personal compensation from Roche/Genentech, UCB, Arialys Therapeutics, Sage Therapeutics; is a consultant for and receives compensation to the Mayo Clinic from Alexion, MedImmune/Viela Bio, and Astellas; receives grant/research Support from Alexion, MedImmue/Viela Bio/Horizon, Grifols, NovelMed, Genentech/Roche, and NIH; is on the advisory board for, and receives compensation to the Mayo Clinic from Alexion, Roche/Genentech; and is on the advisory board for and receives personal compensation from UCB, and Horizon Therapeutics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of ECTRIMS 2022
Share this Video
Related Videos In Neuroimmunology
Anthony Béhin, EAN 2023: Safety Profile Overview of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases
Dr Anthony Béhin (University Hospitals Pitié Salpêtrière, Paris, France) discusses his abstract on the safety profile of anti-FcRn drugs, in particular efgartigimod, and anti-complement drugs in the treatment of IgG-mediated autoimmune diseases. The abstract ‘EPR-128 Safety Profile Overview of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases’ was presented at the annual European Academy […]
Highlights from EAN 2023!
Michael Levy: Highlights from the 75th AAN Annual Meeting, 2023
Dr Michael Levy (Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA) provides his highlights from the 75th AAN Annual Meeting, 2023, in particular that this was the first year to have a myelin oligodendrocyte glycoprotein (MOG) antibody disease focus, with posters on two phase 3 trials, which are expected to be presented in 2026. Disclosures: […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!